#25. David M. Mott Buys $26.7M of ARDELYX, INC. latest buy: 07/18/2016
During the last six months, Mott bet big on ARDX:
David M. Mott
David M. Mott
Ardelyx is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of minimally-systemic therapeutic drugs that work in the gastrointestinal (GI), tract to treat GI and cardio-renal diseases. Co. discovered and designed its primary product candidate, tenapanor, which is being evaluated in clinical studies in patients with constipation-predominant irritable bowel syndrome. Co. is also developing another drug candidate, RDX022, for the treatment of hyperkalemia. In addition, Co. is pursuing other internal discovery and lead-development programs that are in the research phase, including RDX009 Program, RDX013 Program, and RDX011 Program.
Any ideas and opinions presented in all Market News Video clips are for informational and educational purposes
only, and do not reflect the opinions of BNK Invest, Inc. or any of its affiliates, subsidiaries or partners.
In no way should any content contained herein be interpreted to represent trading or investment advice.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. Read Full Disclaimer.